Skip to main content

Table 1 Characteristics of clinical, immunological, and virological parameters, and antiretroviral treatment of vertically HIV-1-infected children.

From: Effects of highly active antiretroviral therapy with nelfinavir in vertically HIV-1 infected children: 3 years of follow-up. Long-term response to nelfinavir in children

  Previous-ART
N. of HIV-children 42
Age (years) (a) 6.7 ± 0.64 (0.5; 16.1)
Male (b) 16 (38.1%)
AIDS diagnosis (CDC) (b) 23 (54.7%)
Baseline CD4 + cell count  
   % CD4+(a) 23.2 ± 1.8 (0.8; 49.7)
   15 – 25% CD4+(b) 13 (22%)
   <15 % CD4+(b) 16 (27.1%)
Baseline HIV-RNA level  
   log10 VL (copies/mL)(a) 4.52 ± 0.11 (3.22; 6.84)
   VL >50,000 copies/mL(b) 14 (33.3%)
ART with NRTI prior-HAART (b)  
   Monotherapy 39 (92.9%)
   Therapy combined 3 (7.1%)
HAART regimen at baseline (b)  
   3TC + d4T + NFV 27 (64.3%)
   AZT + 3TC + NFV 6 (14.3%)
   d4T + ddI + NFV 9 (21.49%)
   New NRTI on HAART  
0 NRTI 14 (33.3%)
1 NRTI 14 (33.3%)
2 NRTI 14 (33.3%)
HAART regimen during follow-up (b)  
   Global adherence (>90%) 100%
   Change of drugs on first line of HAART 9 (21.4%)
Change of NRTI 2 (4.8%)
Adding a NNRTI 4 (9.5%)
Adding a PI 3 (7.1%)
   Stop of HAART with NFV 16 (38.1%)
Change of NFV by other PI 12 (28.6%)
Interruption of HAART 4 (9.5%)
  1. Values are expressed as: a) mean ± s.e.m. (min; max), and b) absolute (percentage). VL: viral load; CDC: Center for Disease Control. HAART: highly active antiretroviral therapy.